Lymphoma by Site — Trials

Lymphoma by Site — Trials · CancerIndex

Clinical trials

Registered studies

900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 250
Recruiting: 134
Ph III recruiting: 7
Growth YoY: +20%
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (130)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03235869	Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma	withdrawn	Early Phase 1	0	University of Michigan Rogel Cancer CenterOTHER	1	Mar 15, 2018	clinicaltrials

Data updated 23 days agoSource updated Mar 15, 2018source: clinicaltrials